f | { | f | { |
| "author": "", | | "author": "", |
| "author_email": "", | | "author_email": "", |
| "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", | | "creator_user_id": "0124c449-4279-4839-a7e2-f7ee873dbc7c", |
| "groups": [ | | "groups": [ |
| { | | { |
| "description": "Group for publications", | | "description": "Group for publications", |
| "display_name": "Publication", | | "display_name": "Publication", |
| "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", | | "id": "816c3c41-f871-427d-9e26-fb21e6b3c578", |
| "image_display_url": | | "image_display_url": |
| mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", | | mw/uploads/group/2022-03-17-123757.433896243660articlesquareicon.png", |
| "name": "publication", | | "name": "publication", |
| "title": "Publication" | | "title": "Publication" |
| } | | } |
| ], | | ], |
| "id": "a48687e2-8216-4daa-982a-066d8c54e55a", | | "id": "a48687e2-8216-4daa-982a-066d8c54e55a", |
| "isopen": false, | | "isopen": false, |
| "license_id": "notspecified", | | "license_id": "notspecified", |
| "license_title": "License not specified", | | "license_title": "License not specified", |
| "maintainer": null, | | "maintainer": null, |
| "maintainer_email": null, | | "maintainer_email": null, |
| "metadata_created": "2021-09-16T08:11:55.197507", | | "metadata_created": "2021-09-16T08:11:55.197507", |
n | "metadata_modified": "2022-04-27T09:37:24.269513", | n | "metadata_modified": "2022-04-27T09:38:14.088655", |
| "name": "malawi-integrated-hiv-program-report-2014-q2", | | "name": "malawi-integrated-hiv-program-report-2014-q2", |
| "notes": "This is the 11th quarterly HIV Program report after | | "notes": "This is the 11th quarterly HIV Program report after |
| implementation of the 2011 Integrated Clinical\r\nHIV Guidelines in | | implementation of the 2011 Integrated Clinical\r\nHIV Guidelines in |
| July 2011. A summary of the key achievements between April and June | | July 2011. A summary of the key achievements between April and June |
| 2014 is\r\nprovided below:\r\n\r\n* Scale-up of integrated HIV | | 2014 is\r\nprovided below:\r\n\r\n* Scale-up of integrated HIV |
| services had reached the following number of sites:\r\n * __724__ | | services had reached the following number of sites:\r\n * __724__ |
| static (579 within and 145 outside of health facilities) and 188 | | static (579 within and 145 outside of health facilities) and 188 |
t | outreach HTC sites\r\n\r\n *__700__ (static) ART sites\r\n\r\n | t | outreach HTC sites\r\n\r\n * __700__ (static) ART sites\r\n\r\n |
| *__615__ PMTCT sites (Option B+, all included in ART sites | | * __615__ PMTCT sites (Option B+, all included in ART sites |
| above)\r\n\r\n *__647__ Pre-ART sites\r\n\r\n * __629__ sites | | above)\r\n\r\n * __647__ Pre-ART sites\r\n\r\n * __629__ sites |
| with HIV-exposed child follow-up\r\n\r\n* __435,976__ persons were | | with HIV-exposed child follow-up\r\n\r\n* __435,976__ persons were |
| tested and counselled for HIV; __136,952 (31%)__ accessed HTC for | | tested and counselled for HIV; __136,952 (31%)__ accessed HTC for |
| the\r\nfirst time; __299,024 (69%)__ were repeat testers and __8,017 | | the\r\nfirst time; __299,024 (69%)__ were repeat testers and __8,017 |
| (3%)__ of these received confirmatory\r\ntesting (after having tested | | (3%)__ of these received confirmatory\r\ntesting (after having tested |
| positive in the past). This is equivalent to __27%__ | | positive in the past). This is equivalent to __27%__ |
| confirmatory\r\ntesting coverage among __29,260__ patients initiating | | confirmatory\r\ntesting coverage among __29,260__ patients initiating |
| ART this quarter. __29,320 (7%)__ clients\r\nreceived a positive | | ART this quarter. __29,320 (7%)__ clients\r\nreceived a positive |
| result for the first time.\r\n\r\n* __18,999 (94%)__ of __20,160__ | | result for the first time.\r\n\r\n* __18,999 (94%)__ of __20,160__ |
| blood units collected were screened for (at least) HIV, hepatitis | | blood units collected were screened for (at least) HIV, hepatitis |
| B\r\nand syphilis.\r\n\r\n* __120,022 (83%)__ of 1__44,408__ women at | | B\r\nand syphilis.\r\n\r\n* __120,022 (83%)__ of 1__44,408__ women at |
| ANC had their HIV status ascertained; __9,146 (8%)__ of\r\nthese were | | ANC had their HIV status ascertained; __9,146 (8%)__ of\r\nthese were |
| HIV positive. __114,585 (95%)__ of __120,794__ women at maternity had | | HIV positive. __114,585 (95%)__ of __120,794__ women at maternity had |
| their HIV status\r\nascertained; 8,407 (7%) of these were HIV | | their HIV status\r\nascertained; 8,407 (7%) of these were HIV |
| positive.\r\n\r\n* __29,260__ patients started ART this quarter. This | | positive.\r\n\r\n* __29,260__ patients started ART this quarter. This |
| 15% increase from the previous quarter\r\n__(25,363)__ was due to | | 15% increase from the previous quarter\r\n__(25,363)__ was due to |
| implementation of new ART eligibility criteria in April 2014.\r\n\r\n* | | implementation of new ART eligibility criteria in April 2014.\r\n\r\n* |
| __505,123__ patients were alive and on ART by end of June 2014. This | | __505,123__ patients were alive and on ART by end of June 2014. This |
| means that 51% of the\r\nestimated 1 million HIV positive population | | means that 51% of the\r\nestimated 1 million HIV positive population |
| was on ART. 1 Estimated ART coverage among\r\npeople in need for | | was on ART. 1 Estimated ART coverage among\r\npeople in need for |
| treatment was __40% (43,931 / 110,000)__for children (<15 years) and | | treatment was __40% (43,931 / 110,000)__for children (<15 years) and |
| __81%\r\n(461,192 / 570,000)__ for adults.\r\n\r\n* __77%__ of adults | | __81%\r\n(461,192 / 570,000)__ for adults.\r\n\r\n* __77%__ of adults |
| and __80%__ of children were retained alive on ART at 12 months after | | and __80%__ of children were retained alive on ART at 12 months after |
| initiation.\r\n\r\n* __436,724 (93%)__ of __469,613__ patients on | | initiation.\r\n\r\n* __436,724 (93%)__ of __469,613__ patients on |
| first line adult ART were on regimen 5A\r\n(TDF/3TC/EFV).\r\n\r\n* | | first line adult ART were on regimen 5A\r\n(TDF/3TC/EFV).\r\n\r\n* |
| __9,406 2 (76%)__ of an estimated __12,425__ HIV infected pregnant | | __9,406 2 (76%)__ of an estimated __12,425__ HIV infected pregnant |
| women in Malawi were on\r\nART this quarter. __4,882 (52%)__ of these | | women in Malawi were on\r\nART this quarter. __4,882 (52%)__ of these |
| were already on ART when getting pregnant and\r\n__4,524 (48%)__ | | were already on ART when getting pregnant and\r\n__4,524 (48%)__ |
| started ART during pregnancy/delivery.\r\n\r\n* An additional | | started ART during pregnancy/delivery.\r\n\r\n* An additional |
| __1,427__breastfeeding women started ART due to Option B+ (in WHO | | __1,427__breastfeeding women started ART due to Option B+ (in WHO |
| stage\r\n1/2)\r\n\r\n* __76%__, __71%__ and __70%__ of women started | | stage\r\n1/2)\r\n\r\n* __76%__, __71%__ and __70%__ of women started |
| under Option B+ were retained on ART at 6, 12 and\r\n24 months after | | under Option B+ were retained on ART at 6, 12 and\r\n24 months after |
| initiation, respectively.\r\n\r\n* __7,743 (7%)__ of infants | | initiation, respectively.\r\n\r\n* __7,743 (7%)__ of infants |
| discharged alive from maternity were known to be HIV exposed, | | discharged alive from maternity were known to be HIV exposed, |
| __7,190\r\n(93%)__ of these received ARV prophylaxis (nevirapine). | | __7,190\r\n(93%)__ of these received ARV prophylaxis (nevirapine). |
| __5,427 (70%)__ were enrolled in exposed\r\nchild follow-up before age | | __5,427 (70%)__ were enrolled in exposed\r\nchild follow-up before age |
| 2 months.\r\n\r\n* A total of __9,153__ HIV exposed children and | | 2 months.\r\n\r\n* A total of __9,153__ HIV exposed children and |
| __7,285__ pre-ART patients were enrolled for followup\r\nin HIV Care | | __7,285__ pre-ART patients were enrolled for followup\r\nin HIV Care |
| Clinics (HCC) during this quarter.", | | Clinics (HCC) during this quarter.", |
| "num_resources": 1, | | "num_resources": 1, |
| "num_tags": 1, | | "num_tags": 1, |
| "organization": { | | "organization": { |
| "approval_status": "approved", | | "approval_status": "approved", |
| "created": "2021-10-14T11:02:35.234558", | | "created": "2021-10-14T11:02:35.234558", |
| "description": "The Department of HIV & AIDS (DHA) was established | | "description": "The Department of HIV & AIDS (DHA) was established |
| in 2001, initially as a unit in the Department of Clinical Services, | | in 2001, initially as a unit in the Department of Clinical Services, |
| to coordinate the biomedical HIV Program in Malawi. The department now | | to coordinate the biomedical HIV Program in Malawi. The department now |
| carries responsibility for various HIV related programs including: | | carries responsibility for various HIV related programs including: |
| sexually transmitted infections (STIs), prevention of mother to child | | sexually transmitted infections (STIs), prevention of mother to child |
| transmission of HIV (PMTCT), and national voluntary male medical | | transmission of HIV (PMTCT), and national voluntary male medical |
| circumcision program (VMMC). All these HIV program sub-sections are | | circumcision program (VMMC). All these HIV program sub-sections are |
| linked to one robust monitoring and evaluation sub-section in the HIV | | linked to one robust monitoring and evaluation sub-section in the HIV |
| and AIDS Department which technically operates under the Central | | and AIDS Department which technically operates under the Central |
| Monitoring and Evaluation Department (CMED) of the Ministry of | | Monitoring and Evaluation Department (CMED) of the Ministry of |
| Health.", | | Health.", |
| "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "image_url": | | "image_url": |
| 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", |
| "is_organization": true, | | "is_organization": true, |
| "name": "dha", | | "name": "dha", |
| "state": "active", | | "state": "active", |
| "title": "Department of HIV & AIDS and Viral Hepatitis", | | "title": "Department of HIV & AIDS and Viral Hepatitis", |
| "type": "organization" | | "type": "organization" |
| }, | | }, |
| "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", |
| "private": false, | | "private": false, |
| "program_area": "Care and Treatment", | | "program_area": "Care and Treatment", |
| "relationships_as_object": [], | | "relationships_as_object": [], |
| "relationships_as_subject": [], | | "relationships_as_subject": [], |
| "resources": [ | | "resources": [ |
| { | | { |
| "cache_last_updated": null, | | "cache_last_updated": null, |
| "cache_url": null, | | "cache_url": null, |
| "created": "2022-03-23T19:55:53.289685", | | "created": "2022-03-23T19:55:53.289685", |
| "description": "", | | "description": "", |
| "format": "PDF", | | "format": "PDF", |
| "hash": "", | | "hash": "", |
| "id": "a8abf31f-9eca-42c2-8d06-6dd4776936e2", | | "id": "a8abf31f-9eca-42c2-8d06-6dd4776936e2", |
| "last_modified": "2022-04-05T00:46:02.580816", | | "last_modified": "2022-04-05T00:46:02.580816", |
| "lfs_prefix": | | "lfs_prefix": |
| "dha/malawi-integrated-hiv-program-report-2014-q2", | | "dha/malawi-integrated-hiv-program-report-2014-q2", |
| "metadata_modified": "2022-04-05T00:46:02.592462", | | "metadata_modified": "2022-04-05T00:46:02.592462", |
| "mimetype": "application/pdf", | | "mimetype": "application/pdf", |
| "mimetype_inner": null, | | "mimetype_inner": null, |
| "name": "malawi-integrated-hiv-program-report-2014-q2", | | "name": "malawi-integrated-hiv-program-report-2014-q2", |
| "package_id": "a48687e2-8216-4daa-982a-066d8c54e55a", | | "package_id": "a48687e2-8216-4daa-982a-066d8c54e55a", |
| "position": 0, | | "position": 0, |
| "resource_type": null, | | "resource_type": null, |
| "sha256": | | "sha256": |
| "80986175db3dce8cd80450395117f6b7cc3b9bac9453b5a5a99f792d99bac7a2", | | "80986175db3dce8cd80450395117f6b7cc3b9bac9453b5a5a99f792d99bac7a2", |
| "size": 1715333, | | "size": 1715333, |
| "state": "active", | | "state": "active", |
| "url": | | "url": |
| d4776936e2/download/malawi-integrated-hiv-program-report-2014-q2.pdf", | | d4776936e2/download/malawi-integrated-hiv-program-report-2014-q2.pdf", |
| "url_type": "upload" | | "url_type": "upload" |
| } | | } |
| ], | | ], |
| "state": "active", | | "state": "active", |
| "tags": [ | | "tags": [ |
| { | | { |
| "display_name": "Report", | | "display_name": "Report", |
| "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", | | "id": "37e5a5df-a993-4d3f-8c9c-73c418c30f0f", |
| "name": "Report", | | "name": "Report", |
| "state": "active", | | "state": "active", |
| "vocabulary_id": null | | "vocabulary_id": null |
| } | | } |
| ], | | ], |
| "title": "Malawi Integrated HIV Program Report 2014 Q2", | | "title": "Malawi Integrated HIV Program Report 2014 Q2", |
| "type": "dataset", | | "type": "dataset", |
| "url": null, | | "url": null, |
| "version": null, | | "version": null, |
| "year": "2014" | | "year": "2014" |
| } | | } |